The prostate cancer treatment market was valued at USD 18.82 billion in 2025 and is projected to reach USD 20.83 billion in 2026 and USD 47.78 billion by 2034, advancing at a CAGR of 10.9% during the forecast period 2026–2034. Market participants include AbbVie Inc., Accord Healthcare, Amgen Inc., Astellas Pharma Inc., AstraZeneca Plc, Bayer AG, Dendreon Pharmaceuticals LLC, Ferring Pharmaceuticals, Ipsen Pharma, Johnson & Johnson Services, Inc., Novartis AG, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Ltd., and Tolmar Pharmaceuticals, Inc. Access to therapy increasingly depends on how drugs are dispensed and how patients are identified, which makes distribution channels and diagnostics central to commercial planning.

Distribution Channel Dynamics in the Prostate Cancer Treatment Market

By distribution channel, the market is segmented into hospital pharmacies, drug stores and retail pharmacies, and online pharmacies. Hospital pharmacies dominated with a 52.0% share in 2025 because of their role in facilitating access to specialized oncology treatments. They ensure proper handling, storage, and dispensing of hormonal treatments, chemotherapy, and targeted therapies under professional supervision, and the presence of oncology departments within hospitals supports preference for this channel, particularly for injectable and infused therapies.

Online pharmacies are experiencing the highest growth rate, at a CAGR of 14.60%, driven by digitalization and a shift toward convenient, home-based healthcare. Easier ordering, enhanced delivery services, and patient support programs have raised their popularity, and the pandemic accelerated adoption of online platforms. Patients taking oral medications, such as hormonal therapies or targeted drugs, increasingly rely on online channels, supported by growing telemedicine and e-prescription use.

Screening, Awareness, and Early Detection

Organizations such as the American Cancer Society and the European Association of Urology have emphasized early screening and regular prostate health checks, including for men aged 50 years and above. Awareness campaigns and expanded prostate cancer screening programs lead to earlier detection, which significantly improves treatment success rates, and they are expected to create lucrative opportunities during the forecast period. Rising investments from government and private entities in innovative screening and diagnostic methods will further drive expansion. Increased awareness has also expanded access to healthcare services, supporting earlier diagnosis and treatment adoption.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/prostate-cancer-treatment-market

Diagnostic Technology and Personalized Care

Enhanced imaging techniques, including multiparametric MRI and PSMA PET-CT, have improved early detection and staging accuracy. Biomarker testing and genomic profiling now inform treatment selection, helping clinicians identify mutations that influence therapeutic response. AI-driven platforms integrate imaging, biomarkers, and pathology to reduce unnecessary biopsies and lessen reliance on subjective clinician judgment, helping to normalize personalized care.

Long-term survivorship is also gaining attention because many treated patients now live for prolonged periods. Survivorship programs can include regular follow-ups, management of urinary and sexual function, psychological counseling, rehabilitation, and educational efforts that maintain patients' quality of life.

Regional Outlook

North America held the largest share of 42.0% in 2025, supported by advanced healthcare infrastructure, strong research and development investment, and early access to targeted therapies and immunotherapies. The American Cancer Society estimated 288,300 new US prostate cancer cases in 2023. Europe accounted for 27.0% of the market in 2025, led by Germany, the UK, and France, where government initiatives promote early diagnosis. Asia Pacific is projected to grow at a CAGR of 13.20%, with China, Japan, and India expanding healthcare infrastructure and adopting modern diagnostic and therapeutic approaches.

Competitive Developments

In June 2026, RadioMedix received FDA approval of its generic Ga-68 PSMA-11 radiodiagnostic, and in April 2026 TOBY, Inc. received FDA Breakthrough Device Designation for a urine-based Multi-Cancer Early Detection test. The high cost of treatments continues to hinder growth, yet digital pharmacy models and diagnostic advances position the prostate cancer treatment market for sustained expansion toward USD 47.78 billion by 2034. Notable trends include adoption of minimally invasive procedures and the use of combination therapies, such as hormonal treatment paired with chemotherapy or immunotherapy, to improve outcomes.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market